DnB Asset Management AS grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,318 shares of the biopharmaceutical company’s stock after buying an additional 1,121 shares during the period. DnB Asset Management AS’s holdings in Alnylam Pharmaceuticals were worth $4,671,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of ALNY. Raymond James Financial Services Advisors Inc. grew its stake in Alnylam Pharmaceuticals by 9.4% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 11,850 shares of the biopharmaceutical company’s stock worth $1,935,000 after buying an additional 1,017 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $1,268,000. Panagora Asset Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 96.4% in the 1st quarter. Panagora Asset Management Inc. now owns 6,565 shares of the biopharmaceutical company’s stock valued at $1,072,000 after purchasing an additional 3,223 shares in the last quarter. Great West Life Assurance Co. Can boosted its stake in shares of Alnylam Pharmaceuticals by 21.2% in the 1st quarter. Great West Life Assurance Co. Can now owns 62,369 shares of the biopharmaceutical company’s stock valued at $10,786,000 after purchasing an additional 10,892 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Alnylam Pharmaceuticals by 1.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 181,271 shares of the biopharmaceutical company’s stock valued at $29,601,000 after purchasing an additional 2,111 shares in the last quarter. Hedge funds and other institutional investors own 94.43% of the company’s stock.
Insider Activity at Alnylam Pharmaceuticals
In related news, CEO Yvonne Greenstreet sold 7,615 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $1,481,802.85. Following the completion of the sale, the chief executive officer now directly owns 30,332 shares in the company, valued at $5,902,303.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 7,615 shares of the business’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $1,481,802.85. Following the completion of the transaction, the chief executive officer now directly owns 30,332 shares in the company, valued at $5,902,303.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jeffrey V. Poulton sold 977 shares of the business’s stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $194.59, for a total transaction of $190,114.43. Following the completion of the transaction, the chief financial officer now owns 11,706 shares of the company’s stock, valued at $2,277,870.54. The disclosure for this sale can be found here. Insiders sold 14,299 shares of company stock worth $2,782,442 over the last three months. 1.40% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
ALNY has been the subject of a number of recent analyst reports. BMO Capital Markets upgraded shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from $200.00 to $250.00 in a report on Friday, May 5th. Morgan Stanley upped their price target on shares of Alnylam Pharmaceuticals from $205.00 to $210.00 and gave the company an “equal weight” rating in a report on Tuesday, April 4th. 92 Resources reiterated an “initiates” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 26th. StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Finally, Sanford C. Bernstein assumed coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, March 21st. They issued an “outperform” rating and a $243.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $247.20.
Alnylam Pharmaceuticals Trading Up 1.5 %
NASDAQ:ALNY opened at $192.57 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $135.46 and a twelve month high of $242.97. The company has a market cap of $23.98 billion, a price-to-earnings ratio of -22.16 and a beta of 0.48. The stock has a fifty day simple moving average of $195.89 and a 200-day simple moving average of $206.82.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.97) by $0.57. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 93.13%. The business had revenue of $319.29 million during the quarter, compared to the consensus estimate of $312.53 million. During the same period last year, the company earned ($2.00) earnings per share. The business’s revenue for the quarter was up 49.7% compared to the same quarter last year. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -6.52 EPS for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alnylam Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Alnylam Pharmaceuticals wasn’t on the list.
While Alnylam Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Which stocks are major institutional investors including hedge funds and endowments buying in today’s market? Click the link below and we’ll send you MarketBeat’s list of thirteen stocks that institutional investors are buying up as quickly as they can.
